-
公开(公告)号：US20180318439A1
公开(公告)日：2018-11-08
申请号：US16045400
申请日：2018-07-25
申请人： Immunomedics, Inc.
IPC分类号： A61K47/68 , C07D491/22 , A61K31/4745 , A61K45/06 , A61N5/10 , C07K16/10 , C07K16/18 , C07K16/30 , C07K16/28 , A61K39/00
CPC分类号： A61K47/6803 , A61K31/4745 , A61K45/06 , A61K47/6841 , A61K47/6849 , A61K47/6851 , A61K47/6853 , A61K47/6855 , A61K47/6857 , A61K47/6861 , A61K47/6889 , A61K2039/505 , A61N5/10 , C07D491/22 , C07K16/1063 , C07K16/18 , C07K16/2803 , C07K16/2833 , C07K16/2863 , C07K16/2887 , C07K16/30 , C07K16/303 , C07K16/3046 , C07K16/3076 , C07K16/3092 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/40 , C07K2317/52 , C07K2317/53 , C07K2317/94 , Y02A50/394 , Y02A50/401 , Y02A50/403 , Y02A50/412 , Y02A50/473 , Y02A50/478
摘要： The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
-
2.发明公开公开(公告)号：US20240352148A1
公开(公告)日：2024-10-24
申请号：US18759739
申请日：2024-06-28
申请人： Immunomedics, Inc.
CPC分类号： C07K16/30 , A61K45/06 , A61K47/6801 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6859 , A61K47/6863 , A61K47/6865 , A61K47/6867 , A61K47/6869
摘要： The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.
-
3.发明公开公开(公告)号：US20240148873A1
公开(公告)日：2024-05-09
申请号：US18473123
申请日：2023-09-22
申请人： IMMUNOMEDICS, INC.
IPC分类号： A61K45/06 , A61K31/337 , A61K31/4184 , A61K31/4375 , A61K31/454 , A61K31/4745 , A61K31/513 , A61K31/675 , A61K31/7088 , A61K31/713 , A61K33/243 , A61K47/68 , C07K16/28 , C07K16/30
CPC分类号： A61K45/06 , A61K31/337 , A61K31/4184 , A61K31/4375 , A61K31/454 , A61K31/4745 , A61K31/513 , A61K31/675 , A61K31/7088 , A61K31/713 , A61K33/243 , A61K47/6803 , A61K47/6849 , A61K47/6851 , A61K47/6853 , C07K16/2803 , C07K16/2833 , C07K16/2887 , C07K16/30 , C07K16/3007 , C07K16/3046 , C07K2317/24 , C07K2317/565 , C07K2317/732 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.
-
公开(公告)号：US11439620B2
公开(公告)日：2022-09-13
申请号：US16204297
申请日：2018-11-29
申请人： Immunomedics, Inc.
IPC分类号： A61K31/35 , A61K31/4745 , A61K31/519 , A61K31/502 , A61K31/337 , A61K39/395 , A61K45/06 , A61K31/357 , A61K31/4184 , A61K31/4375 , A61K31/454 , A61K31/513 , A61K31/675 , A61K31/7088 , A61K31/713 , C07K16/28 , C07K16/30 , A61K47/68 , A61K31/661 , A61K31/52 , A61K33/243
摘要： The present invention relates to combination therapy with ADCs against a tumor-associated antigen, such as Trop-2, and drugs, such as microtubule inhibitors and/or PARP inhibitors. Where ADCs are used, they preferably incorporate SN-38 or another drug that induces DNA strand breaks. Preferably, the combination of ADC and PARPi or microtubule inhibitor exhibits synergistic effects against the cancer. The combination therapy can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy.
-
公开(公告)号：US20220054648A1
公开(公告)日：2022-02-24
申请号：US17397217
申请日：2021-08-09
申请人： Immunomedics, Inc.
IPC分类号： A61K47/68 , A61K31/4745 , A61K39/395 , A61K31/7068 , A61K45/06 , A61K31/337 , A61K31/4184 , A61K31/4375 , A61K31/454 , A61K31/513 , A61K31/675 , A61K31/7088 , A61K31/713 , C07K16/28 , C07K16/30 , A61K41/00 , A61K51/10
摘要： The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to Trop-2 or CEACAM5 and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 16 mg/kg, preferably 4, 6, 8, 9, 10, 12, or 16 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. Surprisingly, the immunoconjugate is effective to treat cancers that are refractory to or relapsed from irinotecan.
-
公开(公告)号：US20210395385A1
公开(公告)日：2021-12-23
申请号：US17338327
申请日：2021-06-03
申请人： Immunomedics, Inc.
摘要： The present invention relates to therapeutic ADCs comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment, more particularly sacituzumab govitecan. The ADC is administered to a subject with a Trop-2 positive cancer that is resistant to or relapsed from prior treatment with a checkpoint inhibitor. The therapy is effective to treat cancers that are resistant to checkpoint inhibitors.
-
公开(公告)号：US11180559B2
公开(公告)日：2021-11-23
申请号：US15868704
申请日：2018-01-11
申请人： Immunomedics, Inc.
IPC分类号： A61K39/00 , C07K16/28 , C07K16/30 , A61K39/395 , A61K9/00 , A61K45/06 , A61K9/08 , C07K16/06 , B82Y5/00
摘要： The present invention concerns compositions and methods of use of anti-HLA-DR antibodies or fragments thereof. In preferred embodiments, the antibodies are subcutaneously administered to a human patient with a hematologic cancer or autoimmune disease. The subcutaneously administered anti-HLA-DR antibody is effective to treat hematologic cancer or autoimmune disease in patients that have relapsed from or are refractory to standard therapies for hematologic cancer or autoimmune disease, such as administration of anti-CD20 antibodies, such as rituximab.
-
公开(公告)号：USRE48751E1
公开(公告)日：2021-09-28
申请号：US16218384
申请日：2018-12-12
申请人： Immunomedics, Inc.
IPC分类号： C07K16/00 , A61K47/68 , A61K31/4745 , A61K45/06 , A61N5/10 , C07D491/22 , C07K16/10 , C07K16/18 , C07K16/28 , C07K16/30 , A61K39/00
摘要： The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
-
9.发明申请公开(公告)号：US20210046185A1
公开(公告)日：2021-02-18
申请号：US17077229
申请日：2020-10-22
申请人： Immunomedics, Inc.
IPC分类号： A61K45/06 , A61K31/4745 , C07K16/30 , A61K31/337 , A61K31/4184 , A61K31/4375 , A61K31/454 , A61K31/513 , A61K31/675 , A61K31/7088 , A61K31/713 , A61K33/24 , C07K16/28 , A61K47/68
摘要： The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an anti-Trop-2 antibody or antigen-binding antibody fragment. In preferred embodiments, the antibody may be an hRS7 antibody. The methods and compostions are of use to treat Trop-2 expressing cancers in human patients, preferably in patients who are resistant to or relapsed from at least one prior anti-cancer therapy, more preferably in patients who are resistant to or relapsed from treatment with irinotecan. The immunoconjugate may be administered at a dosage of 3 mg/kg to 18 mg/kg, preferably 8 to 12 mg/kg, more preferably 8 to 10 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size and reduce or eliminate metastases. Preferred tumors to treat with the subject immunoconjugates include triple-negative breast cancer, HER+, ER+, progesterone+ breast cancer, metastatic non-small-cell lung cancer, a metastatic small-cell lung cancer and metastatic pancreatic cancer.
-
公开(公告)号：US10561738B2
公开(公告)日：2020-02-18
申请号：US15612672
申请日：2017-06-02
申请人： Immunomedics, Inc.
IPC分类号： A61K47/68 , C07K16/10 , C07K16/28 , C07K16/30 , C07D491/22 , A61K31/4745 , C07K16/18 , A61K45/06 , A61N5/10 , A61K39/00
摘要： The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.
-
-
-
-
-
-
-
-
-
搜索结果
670 条记录 (耗时 0.039 秒)
